A NEW jab set to rival the likes of Mounjaro and Wegovy helped people lose up to 22 per cent of their body weight in less ...

A new study found that a combination of hormone therapy and the GLP-1 medication tirzepatide (Zepbound) led to 35% more ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about amylin analogs, retatrutide and more.

An experimental medication was shown to help boost weight loss by up to 20%, a study found. Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to "meaningful, ...

GLP-1 medications, such as Ozempic and Wegovy, have skyrocketed in popularity and are used to treat type 2 diabetes and aid in weight loss. However, studies show they do not work for everyone, ...

Brace yourselves, Ozempic and Zepbound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for retatrutide (nicknamed "Reta"), a brand new GLP-1 weight loss drug that ...

From Ozempic to Wegovy to Mounjaro, injectable weight-loss drugs have become household names — and now there’s a new one everyone is talking about. Retatrutide, a once-weekly experimental injection, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain. In ...

Both the new weight loss drugs and bariatric (weight loss) surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a ...

By Don Thompson for KFF Health News. Broadcast version by Suzanne Potter for California News Service reporting for the KFF ...